Imugene Ltd (ASX:IMU) managing director and chief executive officer Leslie Chong has further demonstrated confidence in the company’s immuno-oncology strategy by purchasing more shares.
Chong purchased 475,240 at 1.8 cents per share on March 16 and now holds 4,387,124 shares and 77,098,765 options.
PD1-Vaxx study
The company’s PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer.
The drug will be trialled in patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer accounting for around 80% of cases.
The study is planned to begin in 2020 and will be conducted at up to 6-10 sites in North America and Australia under a U.S. Food & Drug Administration (FDA) Investigational New Drug (IND) application.
HER-Vaxx trial
The HER-Vaxx trial is targeting HER-2 positive gastric cancer.
To date, the Phase 1b stage of the study has tested three different doses of the HER-Vaxx vaccine in combination with chemotherapy.
All key endpoints were met to identify the optimal dose of HER-Vaxx.
Imugene continues to monitor the enrolment, data collection and the patient’s immune responses to the vaccine.